Cantor sees uniQure as next gene therapy buyout, ups price target to $81.
Cantor Fitzgerald analyst Elemer Piros raised his price target for uniQure (QURE) to $81 from $68 after Roche (RHHBY) acquired Spark Therapeutics (ONCE) for $4.8B. The stock in premarket trading is up 18%, or $7.38, to $48.98. The analyst sees a "number of reasons" why uniQure could be the next gene therapy company to be acquired, "potentially by one of the bidders involved in the Spark sale." uniQure has an established hemophilia pipeline, its pipeline mimics Spark's in many ways, and is a leader in manufacturing, Piros tells investors in a research note. He reiterates an Overweight rating on uniQure.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 25, 2019|
|Previous Article:||NanoLock, Micron collaborate to offer flash-to-cloud management solution.|
|Next Article:||First Majestic reports results from 2018 exploration program at Ermitano project.|